

# Joseph J Saseen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7344128/publications.pdf>

Version: 2024-02-01

155  
papers

7,197  
citations

172207

29  
h-index

60497

81  
g-index

158  
all docs

158  
docs citations

158  
times ranked

9855  
citing authors

#	ARTICLE	IF	CITATIONS
1	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2019, 139, e1082-e1143.	1.6	2,380
2	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. <i>Journal of the American College of Cardiology</i> , 2019, 73, e285-e350.	1.2	1,550
3	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2019, 139, e1046-e1081.	1.6	361
4	American College of Clinical Pharmacy's Vision of the Future: Postgraduate Pharmacy Residency Training as a Prerequisite for Direct Patient Care Practice. <i>Pharmacotherapy</i> , 2006, 26, 722-733.	1.2	261
5	Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2016, 134, e468-e495.	1.6	203
6	Effect of Pharmacist Intervention and Initiation of Home Blood Pressure Monitoring in Patients with Uncontrolled Hypertension. <i>Pharmacotherapy</i> , 2000, 20, 1384-1389.	1.2	143
7	Patient-Level Medication Regimen Complexity Across Populations With Chronic Disease. <i>Clinical Therapeutics</i> , 2013, 35, 385-398.e1.	1.1	133
8	<scp>ACCP</scp> Clinical Pharmacist Competencies. <i>Pharmacotherapy</i> , 2017, 37, 630-636.	1.2	124
9	Gouty Arthritis: A Review of Acute Management and Prevention. <i>Pharmacotherapy</i> , 2016, 36, 906-922.	1.2	85
10	Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2017, 11, 880-890.	0.6	85
11	A Comparison of the Direct Costs and Cost Effectiveness of Serotonin Reuptake Inhibitors and Associated Adverse Drug Reactions. <i>CNS Drugs</i> , 2004, 18, 911-932.	2.7	81
12	Trends in Antihypertensive Medication Monotherapy and Combination Use Among US Adults, National Health and Nutrition Examination Survey 2005â€”2016. <i>Hypertension</i> , 2020, 75, 973-981.	1.3	72
13	Randomized, Placebo-Controlled Trial of Oral Phytonadione for Excessive Anticoagulation. <i>Pharmacotherapy</i> , 2000, 20, 1159-1166.	1.2	71
14	Role of Bempedoic Acid in Clinical Practice. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 853-864.	1.3	71
15	Î²-Blockers. <i>Annals of Pharmacotherapy</i> , 2014, 48, 723-733.	0.9	68
16	Description of Antihypertensive Use in Patients With Resistant Hypertension Prescribed Four or More Agents. <i>Hypertension</i> , 2011, 58, 1008-1013.	1.3	65
17	Comparison of Nifedipine Alone and With Diltiazem or Verapamil in Hypertension. <i>Hypertension</i> , 1996, 28, 109-114.	1.3	63
18	NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. <i>Journal of Clinical Lipidology</i> , 2022, 16, 361-375.	0.6	56

#	ARTICLE	IF	CITATIONS
19	Future Clinical Pharmacy Practitioners Should Be Board-Certified Specialists. <i>Pharmacotherapy</i> , 2006, 26, 1816-1825.	1.2	51
20	Understanding barriers to medication adherence in the hypertensive population by evaluating responses to a telephone survey. <i>Patient Preference and Adherence</i> , 2011, 5, 195.	0.8	51
21	Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2019, 13, 525-537.	0.6	45
22	Impact of the Women's Health Initiative Trial Results on Hormone Replacement Therapy. <i>Pharmacotherapy</i> , 2004, 24, 495-499.	1.2	44
23	Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks. <i>Rheumatology</i> , 2012, 51, 2004-2012.	0.9	43
24	Economic burden of comorbid chronic kidney disease and diabetes. <i>Journal of Medical Economics</i> , 2017, 20, 585-591.	1.0	39
25	Clinical Pharmacists as Key Members of the Patient-Centered Medical Home: An Opinion Statement of the Ambulatory Care Practice and Research Network of the American College of Clinical Pharmacy. <i>Pharmacotherapy</i> , 2014, 34, 96-108.	1.2	38
26	Clinical and economic consequences of statin intolerance in the United States: Results from an integrated health system. <i>Journal of Clinical Lipidology</i> , 2017, 11, 70-79.e1.	0.6	38
27	Recommendations for Managing Drug-Drug Interactions with Statins and HIV Medications. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 375-389.	1.0	36
28	A retrospective cohort study of correlates of response to pharmacologic therapy for hyperlipidemia in members of a managed care organization. <i>Clinical Therapeutics</i> , 2003, 25, 2936-2957.	1.1	31
29	Clinical Pharmacists as Multidisciplinary Health Care Providers in the Management of CKD: A Joint Opinion by the Nephrology and Ambulatory Care Practice and Research Networks of the American College of Clinical Pharmacy. <i>American Journal of Kidney Diseases</i> , 2005, 45, 1105-1118.	2.1	30
30	Venlafaxine-Associated Vaginal Bleeding. <i>Pharmacotherapy</i> , 2002, 22, 652-655.	1.2	29
31	Switching Statin Therapy Using a Pharmacist-Managed Therapeutic Conversion Program versus Usual Care Conversion Among Indigent Patients. <i>Pharmacotherapy</i> , 2008, 28, 553-561.	1.2	29
32	Clinical pharmacists in primary care: Provider satisfaction and perceived impact on quality of care provided. <i>SAGE Open Medicine</i> , 2017, 5, 205031211771391.	0.7	29
33	Zolpidem prescribing practices before and after Food and Drug Administration required product labeling changes. <i>SAGE Open Medicine</i> , 2017, 5, 205031211770768.	0.7	29
34	Lipoprotein(a) and ethnicities. <i>Atherosclerosis</i> , 2022, 349, 42-52.	0.4	29
35	Determining predictors of response to exenatide in type 2 diabetes. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2012, 52, 466-471.	0.7	26
36	Caring for Patients with Chronic Kidney Disease: A Joint Opinion of the Ambulatory Care and the Nephrology Practice and Research Networks of the American College of Clinical Pharmacy. <i>Pharmacotherapy</i> , 2005, 25, 123-143.	1.2	25

#	ARTICLE	IF	CITATIONS
37	Evaluation of medication adherence in chronic disease at a federally qualified health center. <i>Therapeutic Advances in Chronic Disease</i> , 2017, 8, 113-120.	1.1	24
38	Evaluation of the Effect of A Structured Program to Guide Residents's™ Experience in Research (<scp>ASPIRE</scp>) on Pharmacy Residents's™ Knowledge, Confidence, and Attitude toward Research. <i>Pharmacotherapy</i> , 2016, 36, 631-637.	1.2	22
39	Suggested guidelines for pharmacotherapy curricula in family medicine residency training: recommendations from the Society of Teachers of Family Medicine Group on Pharmacotherapy. <i>Family Medicine</i> , 2005, 37, 99-104.	0.3	21
40	Prioritization of Patients for Comprehensive Medication Review By a Clinical Pharmacist in Family Medicine. <i>Journal of the American Board of Family Medicine</i> , 2015, 28, 418-424.	0.8	19
41	Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know. <i>Progress in Cardiovascular Diseases</i> , 2022, 73, 32-40.	1.6	19
42	Postabsorption Concentration Peaks with Brand's Name and Generic Verapamil: A Double's Blind, Crossover Study in Elderly Hypertensive Patients. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 526-534.	1.0	18
43	Incremental increases in economic burden parallels cardiometabolic risk factors in the US. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2016, Volume 9, 233-241.	1.1	18
44	A Pharmacotherapy Capstone Course to Target Student Learning and Programmatic Curricular Assessment. <i>American Journal of Pharmaceutical Education</i> , 2017, 81, 45.	0.7	18
45	Levonorgestrel-Only Dosing Strategies for Emergency Contraception. <i>Pharmacotherapy</i> , 2007, 27, 278-284.	1.2	17
46	Consumer-Driven Health Plans: Impact on Utilization and Expenditures for Chronic Disease Sufferers. <i>Journal of Occupational and Environmental Medicine</i> , 2009, 51, 594-603.	0.9	17
47	Prescription Co-pay Reduction Program for Diabetic Employees. <i>Population Health Management</i> , 2010, 13, 235-245.	0.8	16
48	Simvastatin Prescribing Patterns Before and After FDA Dosing Restrictions: A Retrospective Analysis of a Large Healthcare Claims Database. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 27-34.	1.0	16
49	Categorization of infliximab dose changes and healthcare utilization and expenditures for patients with rheumatoid arthritis in commercially insured and Medicare-eligible populations. <i>Current Medical Research and Opinion</i> , 2009, 25, 303-314.	0.9	15
50	Combination Antiplatelet Agents for Secondary Prevention of Ischemic Stroke. <i>Pharmacotherapy</i> , 2008, 28, 1233-1242.	1.2	14
51	When should COX-2 selective NSAIDs be used for osteoarthritis and rheumatoid arthritis?. <i>Journal of Family Practice</i> , 2006, 55, 260-2.	0.2	14
52	Direct oral anticoagulants versus warfarin in patients with single or double antibody-positive antiphospholipid syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 54, 67-73.	1.0	13
53	An evaluation of the impact of patient cost sharing for antihypertensive medications on adherence, medication and health care utilization, and expenditures. <i>Patient Preference and Adherence</i> , 2012, 6, 63.	0.8	12
54	Evaluation of Statin Prescribing for Secondary Prevention in Primary Care Following New Guideline Recommendations. <i>Annals of Pharmacotherapy</i> , 2016, 50, 17-21.	0.9	12

#	ARTICLE	IF	CITATIONS
55	Dyslipidemia Control in Indigent Patients Receiving Medication Assistance Compared with Insured Patients. <i>Pharmacotherapy</i> , 2008, 28, 562-569.	1.2	11
56	Impact of Student- Versus Instructor-Directed Case Discussions on Student Performance in a Pharmacotherapy Capstone Course. <i>American Journal of Pharmaceutical Education</i> , 2014, 78, 56.	0.7	11
57	Prescribing attitudes, behaviors and opinions regarding metformin for patients with diabetes: a focus group study. <i>Therapeutic Advances in Chronic Disease</i> , 2016, 7, 220-228.	1.1	11
58	Need for a Judicious Use of Nonsteroidal Anti-inflammatory Drugs to Avoid Community-Acquired Acute Kidney Injury. <i>Annals of Pharmacotherapy</i> , 2019, 53, 95-100.	0.9	11
59	A comparison of clinical pharmacist management of type 2 diabetes versus usual care in a federally qualified health center. <i>Pharmacy Practice</i> , 2019, 17, 1618.	0.8	11
60	Prescription copay reduction program for diabetic employees: impact on medication compliance and healthcare costs and utilization. <i>American Health and Drug Benefits</i> , 2009, 2, 14-24.	0.5	11
61	Comparison of New-Onset Gout in Adults Prescribed Chlorthalidone vs Hydrochlorothiazide for Hypertension. <i>Journal of Clinical Hypertension</i> , 2014, 16, 864-868.	1.0	10
62	Comparing Clinical Effectiveness and Drug Toxicity With Hydrochlorothiazide and Chlorthalidone Using Two Potency Ratios in a Managed Care Population. <i>Journal of Clinical Hypertension</i> , 2015, 17, 134-140.	1.0	10
63	Gemfibrozil in Combination with Statins—Is It Really Contraindicated?. <i>Current Atherosclerosis Reports</i> , 2016, 18, 18.	2.0	10
64	Effects of Lipid-Lowering Therapy on Reduction of Cardiovascular Events in Patients with End-Stage Renal Disease Requiring Hemodialysis. <i>Pharmacotherapy</i> , 2010, 30, 823-829.	1.2	9
65	Persistent Use of Against-Label Statin-Fibrate Combinations from 2003–2009 Despite United States Food and Drug Administration Dose Restrictions. <i>Pharmacotherapy</i> , 2012, 32, 623-630.	1.2	9
66	Glycemic Targets and Medication Limitations for Type 2 Diabetes Mellitus in the Older Adult. <i>The Consultant Pharmacist</i> , 2014, 29, 110-123.	0.4	9
67	Curriculum renewal: Alignment of introductory pharmacy practice experiences with didactic course content. <i>Currents in Pharmacy Teaching and Learning</i> , 2017, 9, 1063-1070.	0.4	9
68	Assessing the incidence of acidosis in patients receiving metformin with and without risk factors for lactic acidosis. <i>Therapeutic Advances in Chronic Disease</i> , 2018, 9, 179-190.	1.1	9
69	Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes. <i>Therapeutic Advances in Drug Safety</i> , 2021, 12, 204209862199770.	1.0	9
70	Plant sterols added to combination statin and colessevelam hydrochloride therapy failed to lower low-density lipoprotein cholesterol concentrations. <i>Journal of Clinical Lipidology</i> , 2007, 1, 626-633.	0.6	8
71	Academic pharmacy and patient-centered health care: A model to prepare the next generation of pharmacists. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2011, 51, 194-202.	0.7	8
72	Comparison of faculty assessment and students' self-assessment of performance during clinical case discussions in a pharmacotherapy capstone course. <i>Medical Teacher</i> , 2018, 40, 193-198.	1.0	8

#	ARTICLE	IF	CITATIONS
73	Evaluation of the Clinical Impact of Thromboprophylaxis in Patients With COVID-19 Following Hospital Discharge. <i>Annals of Pharmacotherapy</i> , 2022, 56, 981-987.	0.9	8
74	Dual Calcium-Channel Blocker Therapy in the Treatment of Hypertension. <i>Annals of Pharmacotherapy</i> , 1996, 30, 802-810.	0.9	7
75	Report of the 2009-2010 Professional Affairs Committee: Pharmacist Integration in Primary Care and the Role of Academic Pharmacy. <i>American Journal of Pharmaceutical Education</i> , 2010, 74, S5.	0.7	7
76	Blood pressure control rates measured in specialty vs primary care practices within a large integrated health system. <i>Journal of Clinical Hypertension</i> , 2018, 20, 1253-1259.	1.0	7
77	High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2660-2670.	1.4	7
78	Treatment of Uncomplicated Hypertension: Are ACE Inhibitors and Calcium Channel Blockers as Effective as Diuretics and A-Blockers?. <i>Journal of the American Board of Family Medicine</i> , 2003, 16, 156-a-164.	0.8	6
79	Statins for the Primary Prevention of Cardiovascular Disease in the Elderly. <i>The Consultant Pharmacist</i> , 2015, 30, 20-30.	0.4	6
80	Current Controversies With Recent Cholesterol Treatment Guidelines. <i>Journal of Pharmacy Practice</i> , 2016, 29, 15-25.	0.5	6
81	The importance of clinical research skills according to PharmD students, first-year residents, and residency directors. <i>Currents in Pharmacy Teaching and Learning</i> , 2017, 9, 224-229.	0.4	6
82	Clinical inquiries. Do statins cause myopathy?. <i>Journal of Family Practice</i> , 2003, 52, 973-7.	0.2	6
83	Clinical inquiries. What is the best way to identify patients with white-coat hypertension?. <i>Journal of Family Practice</i> , 2005, 54, 549-50, 552.	0.2	6
84	Clinical inquiries. How effective are lifestyle changes for controlling hypertension?. <i>Journal of Family Practice</i> , 2006, 55, 73-4.	0.2	6
85	ASHP Therapeutic Position Statement on the Daily Use of Aspirin for Preventing Cardiovascular Events. <i>American Journal of Health-System Pharmacy</i> , 2005, 62, 1398-1405.	0.5	5
86	Maintaining Goal Blood Pressures After Switching From Olmesartan to Other Angiotensin Receptor Blockers. <i>Journal of Clinical Hypertension</i> , 2013, 15, 888-892.	1.0	5
87	Monitoring of Recommended Metabolic Laboratory Parameters Among Medicaid Recipients on Second-Generation Antipsychotics in Federally Qualified Health Centers. <i>Annals of Pharmacotherapy</i> , 2018, 52, 160-165.	0.9	5
88	Changes in pharmacy students' perceptions of underserved populations after a six-week clinical rotation in a federally qualified health center clinic. <i>Currents in Pharmacy Teaching and Learning</i> , 2018, 10, 1149-1153.	0.4	5
89	Social and Psychosocial Determinants of Health Associated With Uncontrolled Diabetes in a Federally Qualified Health Center Population. <i>Diabetes Spectrum</i> , 2019, 32, 145-151.	0.4	5
90	Effectiveness of Methenamine for UTI Prevention in Older Adults. <i>Annals of Pharmacotherapy</i> , 2020, 54, 359-363.	0.9	5

#	ARTICLE	IF	CITATIONS
91	Utilization of acute gout prophylaxis in the real world: a retrospective database cohort analysis. <i>Clinical Rheumatology</i> , 2021, 40, 1017-1026.	1.0	5
92	Comparing pre-gap and gap behaviors for Medicare beneficiaries in a Medicare managed care plan. <i>Journal of Health Care Finance</i> , 2011, 38, 38-53.	0.6	5
93	Quality Assessment of Dyslipidemia in Managed Care: Current Best Evidence Should Be Used to Benchmark Quality. <i>Annals of Pharmacotherapy</i> , 2006, 40, 124-127.	0.9	4
94	Pharmacologic Management of Hypertension. , 2013, , 474-489.		4
95	Evaluation of Type 2 Diabetes Mellitus Medication Management and Control in Older Adults. <i>The Consultant Pharmacist</i> , 2013, 28, 296-306.	0.4	4
96	Patterns of serum laboratory monitoring for safety and efficacy in patients on chronic statin therapy. <i>Therapeutic Advances in Drug Safety</i> , 2013, 4, 9-17.	1.0	4
97	Clinic-Level Population Health Intervention by PCY2 Ambulatory Care Pharmacy Residents to Optimize Medication Management in a Self-Insured Employer Health Plan Population. <i>Journal of Pharmacy Practice</i> , 2018, 31, 52-57.	0.5	4
98	Patient considerations in the management of gout and role of combination treatment with lesinurad. <i>Patient Related Outcome Measures</i> , 2018, Volume 9, 231-238.	0.7	4
99	Transatlantic Lipid Guideline Divergence: Same Data But Different Interpretations. <i>Journal of the American Heart Association</i> , 2020, 9, e018189.	1.6	4
100	Clinical inquiries. Does acetaminophen and NSAID combined relieve osteoarthritis pain better than either alone?. <i>Journal of Family Practice</i> , 2004, 53, 501-3.	0.2	4
101	The Performance Gap between Clinical Trials and Patient Treatment for Dyslipidemia. <i>Disease Management and Health Outcomes</i> , 2005, 13, 255-265.	0.3	3
102	Evaluation of fracture risk and potential drug holidays for postmenopausal women on long-term bisphosphonate therapy. <i>International Journal of Women's Health</i> , 2014, 6, 423.	1.1	3
103	Claims analysis of hypertension occurrence, severity changes and patterns of antihypertensive use in cancer patients receiving vascular endothelial growth factor inhibitors. <i>Journal of Oncology Pharmacy Practice</i> , 2015, 21, 258-267.	0.5	3
104	Expanding the pharmacist's scope of practice at the state level: Support for board certification within the credentialing process. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2019, 2, 694-701.	0.5	3
105	Advancing Pharm. D. Training in Egypt through a Structured Preceptor Development Program. <i>Pharmacy (Basel, Switzerland)</i> , 2020, 8, 135.	0.6	3
106	A model for accelerating educational and clinical transformation in primary care by building interprofessional faculty teams: Findings from PACER. <i>Journal of Interprofessional Education and Practice</i> , 2020, 19, 100336.	0.2	3
107	Effectiveness of a pharmacist-led population health approach to implementing statin therapy in primary prevention patients with type 2 diabetes mellitus. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2020, 3, 723-728.	0.5	3
108	An off-site clinical pharmacy service in family medicine: development and 1-year outcomes. <i>Family Medicine</i> , 2014, 46, 348-53.	0.3	3

#	ARTICLE	IF	CITATIONS
109	Low-density lipoprotein cholesterol goal attainment in high-risk family medicine patients. <i>Journal of Clinical Lipidology</i> , 2009, 3, 195-200.	0.6	2
110	Review of Olmesartan Medoxomil in Achieving Guideline-Recommended Target BP Goals and Implications for Managed Care. <i>Current Hypertension Reviews</i> , 2012, 8, 190-195.	0.5	2
111	Bridging health disparities: a national survey of ambulatory care pharmacists in underserved areas. <i>Pharmacy Practice</i> , 2021, 19, 2359.	0.8	2
112	A Just-in-Time Implementation of an Extension for Community Health Outcomes (ECHO) Program for Support of Primary Care During the COVID-19 Pandemic. <i>Journal of the American Board of Family Medicine</i> , 2021, 34, 481-488.	0.8	2
113	Implementation and Assessment of a Novel APPE Intersession Course to Assess Near-Terminal Student Competence. <i>American Journal of Pharmaceutical Education</i> , 2018, 82, 6460.	0.7	2
114	Factors Associated with Antihypertensive Monotherapy Among US Adults with Treated Hypertension and Uncontrolled Blood Pressure Overall and by Race/Ethnicity, NHANES 2013-2018. <i>American Heart Journal</i> , 2021, , .	1.2	2
115	Which is most effective of osteoarthritis of the knee: rofecoxib, celecoxib, or acetaminophen?. <i>Journal of Family Practice</i> , 2002, 51, 307.	0.2	2
116	Clinical inquiries. Do antiarrhythmics prevent sudden death in patients with heart failure?. <i>Journal of Family Practice</i> , 2003, 52, 719-21.	0.2	2
117	Reducing expenditures for statin-type lipid-lowering agents. <i>American Journal of Health-System Pharmacy</i> , 1998, 55, 995-996.	0.5	1
118	Characterization of diabetes risk factors in patients prescribed chronic statin therapy. <i>Therapeutic Advances in Chronic Disease</i> , 2014, 5, 206-211.	1.1	1
119	Assessment of blood pressure in patients with hypertension aged 60â€“79 years before and after the publication of the 2014 Eighth Joint National Committee report. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2016, 10, 67-73.	1.0	1
120	Early impact of the 2018 AHA/ACC/multisociety cholesterol guideline on lipid monitoring after statin initiation. <i>Journal of Clinical Lipidology</i> , 2020, 14, 784-790.	0.6	1
121	Can pharmacists reduce inappropriate emergency department utilization?. <i>American Journal of Health-System Pharmacy</i> , 2020, 77, 1153-1157.	0.5	1
122	Implementation of a distance-based clinical capstone course to improve practice-related confidence and experiential readiness in global Pharm.D. candidates. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2020, 3, 1072.	0.5	1
123	Pharmacistsâ€™ Utilization of Non-HDL-C Levels in Managing Patients With Lipid Disorders. <i>Hospital Pharmacy</i> , 2020, 56, 001857872091038.	0.4	1
124	Retrospective cohort study of statin prescribing for primary prevention among people living with HIV. <i>JRSM Cardiovascular Disease</i> , 2021, 10, 204800402110310.	0.4	1
125	Prescribing practices of migraineâ€™specific pharmacotherapy associated with emergency department use for migraine. <i>Headache</i> , 2021, 61, 455-461.	1.8	1
126	JCL Roundtable. The lipidology team. <i>Journal of Clinical Lipidology</i> , 2022, 16, 3-12.	0.6	1



#	ARTICLE	IF	CITATIONS
127	Clinical inquiries. Do ACE inhibitors prevent nephropathy in type 2 diabetes without proteinuria?. Journal of Family Practice, 2004, 53, 68-9.	0.2	1
128	Epinephrine is efficacious for outpatient treatment of bronchiolitis. Journal of Family Practice, 2004, 53, 175-80.	0.2	1
129	Clinical inquiries. What are effective medication combinations for dyslipidemia?. Journal of Family Practice, 2006, 55, 70-2.	0.2	1
130	Medications Associated with Occurrence of Urinary Tract Infections in Patients with Diabetes, Heart Failure or Both. Current Drug Safety, 2022, 17, .	0.3	1
131	Importance of identifying foreign drugs. American Journal of Health-System Pharmacy, 1999, 56, 2349-2350.	0.5	0
132	What pharmacists need to know about the Women's Health Initiative Estrogen Plus Progestin trial. American Journal of Health-System Pharmacy, 2003, 60, 281-284.	0.5	0
133	Commentary. Evidence-based Cardiovascular Medicine, 2005, 9, 77-78.	0.0	0
134	Chronic Stable Angina: Angiotensin-Converting Enzyme Inhibitor Therapy and/or Calcium-Channel Blocker Therapy—When is it Indicated?. Journal of Pharmacy Technology, 2006, 22, 271-280.	0.5	0
135	Comments on draft of work force document. American Journal of Health-System Pharmacy, 2006, 63, 1592-1592.	0.5	0
136	Which patients are candidates for dipeptidyl peptidase IV inhibitors?. American Journal of Health-System Pharmacy, 2007, 64, 1261-1261.	0.5	0
137	Putting New Disease—Modifying Antirheumatic Drugs into Perspective. Pharmacotherapy, 2007, 27, 1609-1610.	1.2	0
138	Inappropriate Use of Fibrate Therapy in a University-Based Primary Care Clinic Setting*. Journal of Clinical Lipidology, 2011, 5, 213.	0.6	0
139	Use of Diuretics in Women for Management of Hypertension. Current Hypertension Reviews, 2011, 7, 54-58.	0.5	0
140	Entitlement and employability among future pharmacists: Part 2. Pharmacy Today, 2013, 19, 1.	0.0	0
141	Entitlement and employability among future pharmacists: Part 1. Pharmacy Today, 2013, 19, 2.	0.0	0
142	Comparative effectiveness of chlorthalidone with hydrochlorothiazide using two ratios of potency in a real world managed care population. Journal of the American Society of Hypertension, 2014, 8, e28.	2.3	0
143	Simvastatin and CCBs: A Comparison of Prescribing Practices Before and After the U.S. FDA Updates to the 2011 Simvastatin Dosing Standards*. Journal of Clinical Lipidology, 2014, 8, 334.	0.6	0
144	Comparison of new-onset gout incidence in adults prescribed hydrochlorothiazide versus chlorthalidone. Journal of the American Society of Hypertension, 2014, 8, e28-e29.	2.3	0

#	ARTICLE	IF	CITATIONS
145	Assessment of achieved systolic blood pressure in newly treated hypertensive patients aged 60â€“79 years before and after Eighth Joint National Committee recommendations. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2017, 11, 63-71.	1.0	0
146	Assessment of chronic disease management among patients with diabetes and coronary artery disease receiving care in a cardiology clinic. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2018, 1, 89-94.	0.5	0
147	Evaluating a population health approach to statin use: pharmacist driven interventions in patients with type 2 diabetes mellitus*. <i>Journal of Clinical Lipidology</i> , 2019, 13, e31-e32.	0.6	0
148	Identifying patients likely to be referred for a clinical pharmacist intervention in a family medicine residencyâ€“training clinic. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2019, 2, 131-136.	0.5	0
149	JCL roundtable. The 2018 AHA/ACC/Multisociety Cholesterol Guidelines: Process and product. <i>Journal of Clinical Lipidology</i> , 2019, 13, 345-355.	0.6	0
150	Early impact of 2018 AHA/ACC/Multisociety Cholesterol Guideline on lipid monitoring after statin initiation. <i>Journal of Clinical Lipidology</i> , 2021, 15, e4.	0.6	0
151	Does use of oxytocin and dinoprostone inserts shorten labor more than use of oxytocin after removal of dinoprostone?. <i>Journal of Family Practice</i> , 2002, 51, 479.	0.2	0
152	Does acetaminophen affect liver function in alcoholic patients?. <i>Journal of Family Practice</i> , 2003, 52, 187-8.	0.2	0
153	Is rate control better than rhythm control for atrial fibrillation in older high-risk patients?. <i>Journal of Family Practice</i> , 2003, 52, 192, 194.	0.2	0
154	Clinical inquiries. What is the best regimen for newly diagnosed hypertension?. <i>Journal of Family Practice</i> , 2005, 54, 281-2.	0.2	0
155	Which lipoprotein measurements are clinically useful?. <i>American Family Physician</i> , 2007, 75, 387-8.	0.1	0